Magnetic resonance spectroscopic imaging: Current status in the management of prostate cancer

BJU International

Volumn 103, Issue 12, 2009, Pages 1614-1620

  Nayyar, Rishi ^b   Kumar, Rajeev ^b   Kumar, Virendra ^a   Jagannathan, Naranamangalam R ^a   Gupta, Narmada P ^b   Hemal, Ashok K ^b  

^a Departments of Urology

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Magnetic resonance spectroscopy; Prostate cancer; Prostate cancer imaging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CRYOTHERAPY; FOLLOW UP; HUMAN; INFORMATION PROCESSING; LYMPH NODE METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT PLANNING; TUMOR VOLUME;

HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM STAGING; PROSTATE; PROSTATIC NEOPLASMS;

EID: 67149105635     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08446.x     Document Type: Review

References (43)

1. Sharma U, Jagannathan NR. Potential of in vivo Magnetic Resonance Spectroscopy (MRS) in medicine. Proc Indian Natl Sci Acad A 2004 70A : 555 77
2. Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate: hormonal relationships in normal and neoplastic prostate. Prostate 1991 19 : 181 205
3. Costello LC, Franklin RB. The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000 59 : 269 82
4. Cooper JF, Farid I. The role of citric acid in the physiology of the prostate: lactic-citrate ratios in benign and malignant prostatic homogenates as an index of prostatic malignancy. J Urol 1964 92 : 533 6
5. Rifkin MD. MRI of the prostate. Crit Rev Diagn Imaging 1990 31 : 223 62
6. Mazaheri Y, Dave AS, Muellner A, Hricak H. MR imaging of the prostate in clinical practice. MAGMA 2008 21 : 379 92
7. Kurhanewicz J, Vigneron DB, Nelson SJ et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995 45 : 459 66
8. 3) spatial resolution. Radiology 1996 198 : 795 805 (Pubitemid 26066301)
9. Parivar F, Hricak H, Shinohar K et al. Detection of locally recurrent prostate cancer after cryotherapy: evaluation by transrectal ultrasound, magnetic resonance imaging and three dimensional proton magnetic resonance spectroscopy. Urology 1996 48 : 594 9
10. Males RG, Vigneron DB, StarLack J et al. Clinical application of BASING and spectral-spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000 43 : 17 22 (Pubitemid 30027108)
11. Kumar R, Kumar M, Jagannathan NR, Gupta NP, Hemal AK. Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate. Urol Res 2004 32 : 36 40 (Pubitemid 38314143)
12. vanDorsten FA, van der Graaf M, Engelbrecht MR et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004 20 : 279 87
13. Van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 2000 10 : 153 9
14. Shukla-Dave A, Hricak H, Moskowitz C et al. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 2007 245 : 499 506 (Pubitemid 47612532)
15. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate. MR imaging and spectroscopy. Present Future Radiol Clin North Am 2000 38 : 115 38
16. Sheidler J, Hricak H, Vigneron DB et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging- clinicopathologic study. Radiology 1999 213 : 473 80
17. Zakian KL, Eberhardt S, Hricak H et al. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging-initial results. Radiology 2003 229 : 241 7
18. Fütterer JJ, Scheenen TW, Heijmink SW et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007 42 : 116 22
19. Wefer AE, Hricak H, Vigneron DB et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000 164 : 400 5
20. Swanson MG, Vigneron DB, Tabatabai L et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI-3D- MRSI-targetted postsurgical prostate tissues. Magn Reson Med 2003 50 : 944 54
21. 1H MRSI based TRUS guided biopsies in men with suspected prostate cancer. Proc Intl Soc Mag Reson Med 2006 14 : 1790
22. Kumar R, Nayyar R, Kumar V et al. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng-ml: a follow-up study. Urology 2008 72 : 859 63
23. Naughton CK, Smith DS, Humphrey PA, Catalona WJ, Keetch DW. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 1998 52 : 808 13
24. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false negative sextant prostate biopsies. J Urol 1998 159 : 1247 50
25. Kumar V, Jagannathan NR, Kumar R et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three dimensional 1H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng-ml. NMR Biomed 2007 20 : 11 20 (Pubitemid 46332437)
26. Coakley FV, Kurhanewicz J, Lu Y et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002 223 : 91 7
27. Beyersdorff D, Winkel A, Hamm B, Lenk S, Loening SA, Taupitz M. MR imaging-guided prostate biopsy with a closed MR Unit at 1.5 T: initial results. Radiology 2005 234 : 576 81
28. Yuen JSP, Thng CH, Tan PH et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 2004 171 : 1482 6
29. Prando A, Kurhanewicz J, Borges AP, Oliveira EM Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005 236 : 903 10
30. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002 16 : 451 63
31. Zakian KL, Sircar K, Hricak H et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005 234 : 804 14
32. Bartolozzi C, Menchi I, Lencioni R et al. Local staging of prostate carcinoma with endorectal coil MRI: correlation with whole mount radical prostatectomy specimens. Eur Radiol 1996 6 : 339 45
33. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek C, Nelson S. Improved prediction of extracapsular extension in patients with prostate cancer by the addition of 3D H1-MR spectroscopic imaging to MR imaging. Radiology 1999 213 : 481 8
34. Hricak H. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol 2005 78 : S103 11
35. Zaider M, Zelefsky MJ, Lee EK et al. Treatment planning for prostate implants using magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2000 47 : 1085 96
36. Scharen-Guivek VLM, Males R, Nelson SJ, Mueller-Lisse UG, Vigneron DB, Kurhanewicz J. Evaluation of local prostate recurrence after radical prostatectomy using magnetic resonance spectroscopic imaging. Presented at the Seventh Annual Meeting of The International Society for Magnetic Resonance in Medicine, Philadelphia, PA, 1999
37. Bessette A, Mueller-Lisse UG, Swanson M et al. Localization of prostate cancer after hormonal ablation by MRI and 3D 1H- MRSI. Case control study with pathological correlation. Presented at the Seventh Annual Meeting of The International Society for Magnetic Resonance in Medicine, Philadelphia, PA, 1999 1519
38. Males R, Okuno W, Vigneron DB et al. Monitoring effects of prostate cancer brachytherapy using combined MRI-MRS. Presented at the Seventh Annual Meeting of The International Society for Magnetic Resonance in Medicine, Philadelphia, PA, 1999
39. Parivar F, Kurhanewicz J. Detection of recurrent prostate cancer after cryosurgery. Curr Opin Urol 1998 8 : 83 6
40. Kurhanewicz J, Vigneron DB, Hricak H et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H1MR spectroscopic imaging. Radiology 1996 200 : 489 96
41. Pickett B, Kurhanewicz J, Coakley F et al. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004 60 : 1047 55
42. Kumar V, Jagannathan NR, Kumar R et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn Reson Imaging 2006 24 : 541 8
43. Kumar V, Jagannathan NR, Kumar R et al. 3D 1H MR spectroscopic imaging and diffusion weighted imaging of prostate in men with raised PSA. Eur Biophys J 2005 32 : 761